نتائج البحث - Sumana Devata

  • يعرض 1 - 4 نتائج من 4
تنقيح النتائج
  1. 1
    Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

    Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial حسب Asra Ahmed, Samuel A. Merrill, Fares Alsawah, Paula Bockenstedt, Erica Campagnaro, Sumana Devata, Scott D. Gitlin, Mark Kaminski, Alice Cusick, Tycel Phillips, Suman L. Sood, Moshe Talpaz, Albert Quiery, Philip S. Boonstra, Ryan A. Wilcox

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial

    Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Tre... حسب Sameh Gaballa, Ranjit Nair, Ryan Jacobs, Sumana Devata, Seok‐Goo Cho, Don A. Stevens, Dok Hyun Yoon, Nirav N. Shah, Denise Brennan, Jason Law, Robert Chen, David Sermer, Robin Lesley, Ben Buelow, Alessandra Forcina, Jing‐Zhou Hou

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

    Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma حسب Auris Huen, Bradley M. Haverkos, Jasmine M. Zain, Radhakrishnan Ramchandren, Mary Jo Lechowicz, Sumana Devata, Neil J. Korman, Lauren Pinter‐Brown, Yasuhiro Oki, Prajak J. Barde, Ajit Nair, Kasi V. Routhu, Srikant Viswanadha, Swaroop Vakkalanka, Swaminathan P. Iyer

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

    A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma حسب Nancy L. Bartlett, Alex F. Herrera, Eva Domingo‐Domènech, Amitkumar Mehta, Andres Forero‐Torres, Ramón García‐Sánz, Philippe Armand, Sumana Devata, Antonia Rodríguez Izquierdo, Izidore S. Lossos, Craig B. Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, András Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: